Arjo (ARJO) Q2 2026 earnings summary

Executive summary

• Achieved 4.7% organic sales growth in Q2 2026, driven by strong global demand, especially in patient handling, medical beds, and services, with notable performance in North America, France, Australia, and the UK.

• ReNu business reached record sales, reflecting rising demand for sustainable healthcare solutions.

• Adjusted EBITDA increased to SEK 482 million (475), and adjusted EBIT rose to SEK 211 million (208) compared to Q2 2025.

• Strategic actions included appointing five new regional leaders to enhance customer focus, efficiency, and profitability.

• Cash flow from operations improved to SEK 257 million (205), with cash conversion at 53.3% (46.6%).

Financial highlights

• Net sales reached SEK 2,759 million (2,678), with organic growth of 4.7% year-over-year.

• Gross margin declined to 42.1% (43.4%) due to unfavorable mix and higher material and transport costs.

• Adjusted EBITDA margin was 17.5% (17.7%), and adjusted EBIT margin was 7.7% (7.8%).

• Earnings per share increased to SEK 0.46 (0.34).

• Operating cash flow increased to SEK 257 million, up SEK 52 million year-over-year.

Outlook and guidance

• Organic sales growth for 2026 is expected within the 3-5% target range.

• Strong demand expected to continue globally, with a robust pipeline for the second half.

• Strategy and value creation targets to be detailed at the Capital Markets Day in September.

• Cost control and efficiency remain key focus areas for the remainder of the year.